Marker Therapeutics (MRKR) Competitors $1.05 -0.01 (-0.94%) As of 11:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRKR vs. LTRN, PDSB, AADI, MDCX, NBRV, SCYX, TELO, ESLA, IPSC, and RNXTShould you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include Lantern Pharma (LTRN), PDS Biotechnology (PDSB), Aadi Bioscience (AADI), Medicus Pharma (MDCX), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Telomir Pharmaceuticals (TELO), Estrella Immunopharma (ESLA), Century Therapeutics (IPSC), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical products" industry. Marker Therapeutics vs. Its Competitors Lantern Pharma PDS Biotechnology Aadi Bioscience Medicus Pharma Nabriva Therapeutics SCYNEXIS Telomir Pharmaceuticals Estrella Immunopharma Century Therapeutics RenovoRx Marker Therapeutics (NASDAQ:MRKR) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Do analysts rate MRKR or LTRN? Marker Therapeutics currently has a consensus price target of $13.17, suggesting a potential upside of 1,153.97%. Lantern Pharma has a consensus price target of $25.00, suggesting a potential upside of 436.02%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Marker Therapeutics is more favorable than Lantern Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable valuation and earnings, MRKR or LTRN? Marker Therapeutics has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarker Therapeutics$6.59M2.06-$10.73M-$1.37-0.77Lantern PharmaN/AN/A-$20.78M-$1.78-2.62 Do institutionals and insiders have more ownership in MRKR or LTRN? 22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 7.8% of Marker Therapeutics shares are held by insiders. Comparatively, 8.5% of Lantern Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer MRKR or LTRN? In the previous week, Marker Therapeutics had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for Marker Therapeutics and 1 mentions for Lantern Pharma. Marker Therapeutics' average media sentiment score of 0.75 beat Lantern Pharma's score of 0.00 indicating that Marker Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is MRKR or LTRN more profitable? Lantern Pharma has a net margin of 0.00% compared to Marker Therapeutics' net margin of -271.12%. Lantern Pharma's return on equity of -99.89% beat Marker Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Marker Therapeutics-271.12% -114.59% -90.31% Lantern Pharma N/A -99.89%-81.58% Which has more risk and volatility, MRKR or LTRN? Marker Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. SummaryMarker Therapeutics beats Lantern Pharma on 10 of the 16 factors compared between the two stocks. Get Marker Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRKR vs. The Competition Export to ExcelMetricMarker TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.59M$2.65B$6.14B$10.61BDividend YieldN/A56.92%5.70%4.74%P/E Ratio-0.7723.5885.4027.05Price / Sales2.06769.38619.93137.41Price / CashN/A169.9037.7861.77Price / Book0.615.5213.286.71Net Income-$10.73M$32.78M$3.30B$276.44M7 Day Performance15.56%6.30%4.65%3.15%1 Month Performance20.10%13.24%9.40%9.61%1 Year Performance-60.08%0.08%89.07%35.25% Marker Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRKRMarker Therapeutics4.0745 of 5 stars$1.05-0.9%$13.17+1,154.0%-61.9%$13.59M$6.59M-0.7760Short Interest ↓Gap UpLTRNLantern Pharma2.0486 of 5 stars$4.54+2.0%$25.00+450.7%+22.0%$48.11MN/A-2.5520PDSBPDS Biotechnology1.6993 of 5 stars$1.01-1.0%$10.00+890.1%-74.2%$47.97MN/A-1.1020AADIAadi BioscienceN/A$1.94+2.6%N/A+10.8%$47.91M$25.07M-0.8540MDCXMedicus Pharma2.7439 of 5 stars$2.51-4.6%$23.50+836.3%N/A$46.86MN/A-1.87N/ANBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070SCYXSCYNEXIS0.688 of 5 stars$1.05-2.3%N/A-46.8%$45.07M$3.75M-2.6260Gap UpTELOTelomir Pharmaceuticals3.1562 of 5 stars$1.34-3.6%$15.00+1,019.4%-67.0%$44.87MN/A-2.481News CoverageShort Interest ↓Gap DownESLAEstrella Immunopharma2.5629 of 5 stars$1.19-0.8%$16.00+1,244.5%+13.5%$44.48MN/A-4.58N/APositive NewsGap UpIPSCCentury Therapeutics2.4532 of 5 stars$0.50-1.9%$3.75+650.6%-62.3%$43.98M$6.59M-1.72170News CoverageGap UpRNXTRenovoRx1.7694 of 5 stars$1.18flat$7.50+535.6%+14.0%$43.24M$662K-3.116Gap Up Related Companies and Tools Related Companies Lantern Pharma Alternatives PDS Biotechnology Alternatives Aadi Bioscience Alternatives Medicus Pharma Alternatives Nabriva Therapeutics Alternatives SCYNEXIS Alternatives Telomir Pharmaceuticals Alternatives Estrella Immunopharma Alternatives Century Therapeutics Alternatives RenovoRx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRKR) was last updated on 10/8/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"If I'm right about what's coming, this could be the most important book you'll read this yearCrypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
